Advanced Search:
Equity Index

AB.PA - AB SCIENCE

€2.01  0.028 (1.42%)

Updated: 08:44 May 10, 2024 EST

Next Session's AI Forecast

89.41%

Avg. Accuracy (AI)

€1.75

Next Week's AI Forecast

50%

Trend's Accuracy (AI)

€1.96

AB SCIENCE's Position Within the Drug Manufacturers—Specialty & Generic Industry
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)

AB SCIENCE - HISTORICAL DATA 6M

  • Last price

    €2.01

  • Daily change

    €0.028

  • Previous Close

    €1.982

  • Last Updated

    08:44 May 10, 2024 EST

CURRENT VOLATILITY

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
0.15 -0.52 -0.96 -0.24 -0.37

CURRENT VOLATILITY RANK

Variation from the lowest to the highest value in a period.

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
1.36 1.96 3.57 3.56 3.6

STOCHASTIC METRIC

The STOCHASTIC METRIC shows when a financial asset has moved into an overbought or oversold position.

OVERSOLD
OVERBOUGHT
Curr. Week Next Week Curr. Month Curr. Quarter
0% 63.64% 27.53% 5.76%

MOVING AVERAGE METRIC

5 Sessions Change 5 Sessions 20 Sessions Change 20 Sessions 50 Sessions Change 50 Sessions 200 Sessions
2 2.04% 1.96 -9.26% 2.16 -22.3% 2.78

RSI METRIC

RS Hour RSI Hour RS Day RSI Day
2 50 1 66.67

AB SCIENCE Technical Analysis News

AB SCIENCE

3, avenue George V
Paris 75008
France
33 1 47 20 00 14
https://www.ab-science.com

Sectors: Healthcare
Industry: Drug Manufacturers—Specialty & Generic
F. Time Employees: 89
Description

AB Science S.A., a pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. Its lead compound is the masitinib, a tyrosine kinase inhibitor that is in Phase III clinical trials for the treatment of prostate and pancreatic cancer, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's, severe asthma, and mastocytosis diseases, as well as in Phase II clinical trial to treat Covid-19. The company is also developing AB8939, a synthetic microtubule destabiliser for haematology indications. The company markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.

Corporate Governance

AB Science S.A.’s ISS Governance QualityScore as of May 1, 2024 is 10. The pillar scores are Audit: 10; Board: 10; Shareholder Rights: 10; Compensation: 10.

AB SCIENCE'S HOLDERS RANK

List of holders with stock participation in AB SCIENCE.

Holder Rank Holder Shares Date Reported % Out Value